Last reviewed · How we verify
Intranasal dexmedetomidine
At a glance
| Generic name | Intranasal dexmedetomidine |
|---|---|
| Also known as | · Dexmedetomidine nasal spray · Intranasal dexmedetomidine · Dexmedetomidine intranasal spray · Dexmedetomidine intranasal group (D group), Propofol 2 mg/kg, fentanyl 1 µg/kg, Cis-atracurium 0.15mg / kg, Isoflurane 1-1.5% in 50% oxygen |
| Sponsor | Sun Fei |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- Analgosedation With Ketamine, Nalbuphine, or Dexmedetomidine for Suture Removal in Children After Cleft Surgery (NA)
- The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder (NA)
- Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children (PHASE4)
- Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia (PHASE4)
- IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures (EARLY_PHASE1)
- Comparison of Intranasal Dexmedetomidine and Short Video Viewing in the Preoperative Anxiety
- Children of Age 2-6years Undergoing Elective Surgery Will be Divided Into Two Groups Randomly. This Study Aims to Evaluate if Intranasal Dexmedetomidine is Better Than Intranasal Ketamine in Producing Sedation and Reducing Parent Separation Anxiety Before Surgery. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal dexmedetomidine CI brief — competitive landscape report
- Intranasal dexmedetomidine updates RSS · CI watch RSS
- Sun Fei portfolio CI